Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans.

[1]  M Fujita,et al.  Test-retest reproducibility of extrastriatal dopamine D2 receptor imaging with [123I]epidepride SPECT in humans. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  Robert B. Innis,et al.  Kinetic and equilibrium analyses of [123I]epidepride binding to striatal and extrastriatal dopamine D2 receptors , 1999 .

[3]  J. Seibyl,et al.  Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D2 receptor binding with [123I]epidepride SPECT. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  Bernard Bendriem,et al.  Quantitation of Extrastriatal D2 Receptors Using a Very High-Affinity Ligand (FLB 457) and the Multi-Injection Approach , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  W. Sadee,et al.  Sequestration of dopamine D2 receptors depends on coexpression of G-protein-coupled receptor kinases 2 or 5. , 1999, European journal of biochemistry.

[6]  A. Rivera,et al.  Differential regional and cellular distribution of dopamine D2‐like receptors: An immunocytochemical study of subtype‐specific antibodies in rat and human brain , 1998, The Journal of comparative neurology.

[7]  I G Zubal,et al.  Significance of nonuniform attenuation correction in quantitative brain SPECT imaging. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  G Blomqvist,et al.  Comparison of the Transient Equilibrium and Continuous Infusion Method for Quantitative PET Analysis of [11C]Raclopride Binding , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  M. Laruelle,et al.  SPECT Imaging of Resting Dopamine Synaptic Release in the Striatum of Untreated Schizophrenic Patients , 1998, NeuroImage.

[10]  F. Gonon,et al.  Internalization of D1 Dopamine Receptor in Striatal NeuronsIn Vivo as Evidence of Activation by Dopamine Agonists , 1998, The Journal of Neuroscience.

[11]  S Eberl,et al.  Effects of scatter and attenuation correction on quantitative assessment of regional cerebral blood flow with SPECT. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Christer Halldin,et al.  A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients , 1997, Psychopharmacology.

[13]  W C Eckelman,et al.  Kinetic Modeling of [11C]Raclopride: Combined PET-Microdialysis Studies , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  Marc Laruelle,et al.  Imaging D2 Receptor Occupancy by Endogenous Dopamine in Humans , 1997, Neuropsychopharmacology.

[15]  Christer Halldin,et al.  Effect of reserpine‐induced depletion of synaptic dopamine on [11C]Raclopride binding to D2‐dopamine receptors in the monkey brain , 1997, Synapse.

[16]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Philip D. Harvey,et al.  Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. , 1997, Psychopathology.

[18]  Christer Halldin,et al.  Autoradiographic localization of extrastriatal D2‐dopamine receptors in the human brain using [125I]epidepride , 1996, Synapse.

[19]  J. Wamsley,et al.  Time dependent changes in DA uptake sites, D1 and D2 receptor binding and mRNA after 6-OHDA lesions of the medial forebrain bundle in the rat brain , 1995, Journal of Chemical Neuroanatomy.

[20]  A. D. Smith,et al.  Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: Light and electron microscopy , 1995, Neuroscience.

[21]  M. K. Das,et al.  Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. , 1995, Nuclear medicine and biology.

[22]  P B Hoffer,et al.  Reproducibility of SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  E. Sybirska,et al.  Pharmacokinetics of the three radioiodinated dopamine D2 receptor ligands [123I]IBF, [123I]epidepride and [123I]2'-ISP in nonhuman primates. , 1994, Nuclear medicine and biology.

[24]  Jean Logan,et al.  Imaging endogenous dopamine competition with [11C]raclopride in the human brain , 1994, Synapse.

[25]  Comparison of three high affinity SPECT radiotracers for the dopamine D2 receptor. , 1994, Nuclear medicine and biology.

[26]  J. Mazziotta,et al.  MRI‐PET Registration with Automated Algorithm , 1993, Journal of computer assisted tomography.

[27]  J. Haycock,et al.  Four isoforms of tyrosine hydroxylase are expressed in human brain , 1993, Neuroscience.

[28]  M. Ansari,et al.  High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. , 1993, Life sciences.

[29]  J R Votaw,et al.  Visualization of extrastriatal dopamine D2 receptors in the human brain. , 1992, European journal of pharmacology.

[30]  E. Sybirska,et al.  Pharmacokinetics of the SPECT benzodiazepine receptor radioligand [123I]iomazenil in human and non-human primates. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[31]  R R MacGregor,et al.  GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[32]  Marc Laruelle,et al.  Amphetamine‐stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates , 1992, Synapse.

[33]  K. Davis,et al.  Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.

[34]  J S Fowler,et al.  Amphetamine induced decreases in (18F)‐N‐methylspiroperidol binding in the baboon brain using positron emission tomography (PET) , 1991, Synapse.

[35]  J. Palacios,et al.  Dopamine receptors in human brain: Autoradiographic distribution of D2 sites , 1989, Neuroscience.

[36]  L. Farde,et al.  Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[37]  G. Reynolds,et al.  Beyond the Dopamine Hypothesis , 1989, British Journal of Psychiatry.

[38]  P. Seeman,et al.  Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain , 1989, Synapse.

[39]  M. Phelps,et al.  In vivo [3H]Spiperone Binding: Evidence for Accumulation in Corpus Striatum by Agonist-Mediated Receptor Internalization , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[40]  D. Weinberger.  Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.

[41]  M. Savasta,et al.  Autoradiographic distribution of the D1 agonist [3H]SKF 38393, in the rat brain and spinal cord. Comparison with the distribution of D2 dopamine receptors , 1986, Neuroscience.

[42]  P. Randall,et al.  D-2 dopamine receptors in aging mouse striatum: determination of high- and low-affinity agonist binding sites. , 1985, The Journal of pharmacology and experimental therapeutics.

[43]  P. Seeman,et al.  Agonist high- and low-affinity states of the D2-dopamine receptor in calf brain. Partial conversion by guanine nucleotide. , 1984, Molecular pharmacology.

[44]  J. Elsworth,et al.  Relative Importance of 3‐Methoxy‐4‐Hydroxyphenylglycol and 3,4‐Dihydroxyphenylglycol as Norepinephrine Metabolites in Rat, Monkey, and Humans , 1983, Journal of neurochemistry.

[45]  D. Sibley,et al.  Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. , 1982, The Journal of biological chemistry.

[46]  S H Snyder,et al.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs , 1976, Science.

[47]  P. Seeman,et al.  Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. , 1975, Science.